Share

Profile & Fundamentals

Roche Holding Profile & Fundamentals

Name: Roche Holding financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.

Company profile record

Roche Holding AG

Common Stock · Health Care · Pharmaceuticals

Official website

Company

Company / asset: Roche Holding AG
Security type: Common Stock
Sector: Health Care
Industry: Pharmaceuticals
HQ: 🇨🇭 Switzerland
Head office: Grenzacherstrasse 124, Basel, Switzerland, 4070

Leadership & scale

Chief executive: Dr. Thomas Schinecker
CEO year born: 1975
Full-time employees: 103.2K
Fiscal year end: December

Fundamentals snapshot

Updated 2026-08-12

Market Cap: CHF 288.7B
P/E: 13.3x
Revenue (Q2 26): CHF 30.4B
Profit (Q2 26): CHF 6.9B
Dividend Yield: 1.8%
Revenue (FY 25): CHF 61.5B
Shares in public float: 654M
Insider ownership: 0%

Reporting & identifiers

Symbol: ROG.SIX
Listing: 🇨🇭 Switzerland | Dividend Tax: 35%
Ticker Currency: CHF
Income Statement Currency: CHF
Balance Sheet Currency: CHF
Cash Flow Currency: CHF
EPS Currency: CHF
Contract Type: SPOT
ISIN: CH0012032048
Asset ID: equity_73fd14fb-d2e2-59fd-a5e4-45499d17e077

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The headline earnings story seems confusing at first glance because reported Swiss franc revenues slipped while operating profits climbed. For fiscal 2025, reported sales edged down one percent to 61.5 billion Swiss francs, yet constant-currency sales expanded seven percent. Net profit rebounded sharply to 12.9 billion francs as prior-year write-downs faded. This performance shows that the underlying commercial engine is fundamentally sound. Rapid volume gains from newer blockbusters easily offset generic competition on older cancer therapies. Over fourteen billion francs in annual free cash flow proves that the business continues to generate high-quality, recurring cash.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

Profit margins demonstrated impressive resilience in 2025 as the company successfully transitioned away from post-pandemic disruptions. Gross margins held remarkably firm near seventy-four percent, proving that customer demand for proprietary specialty medicines remains insensitive to broader inflation. Operating margin rebounded sharply to thirty-one percent as temporary restructuring costs and inventory charges ended. Favorable product mix shifts toward premium specialty medicines and high-margin diagnostic reagents provide structural operating leverage. This dual-engine business model successfully defends company profitability against mandatory government pricing reforms and generic biosimilar competition.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-08-13.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	51,603,921,568.63	10,644,117,647.06	9,388,235,294.12	71.35	32.01	18.19	20.63
2017-12-31	57,234,086,242.3	14,902,464,065.71	8,863,449,691.99	71.5	31.03	15.49	26.04
2018-12-31	60,587,576,374.75	16,228,105,906.31	10,692,464,358.45	72.23	31.8	17.65	26.78
2019-12-31	65,858,471,074.38	19,506,198,347.11	13,943,181,818.18	72.73	32.99	21.17	29.62
2020-12-31	65,901,694,915.25	12,960,451,977.4	16,152,542,372.88	71.96	30.4	24.51	19.67
2021-12-31	68,860,745,614.04	17,565,789,473.68	15,274,122,807.02	68.63	28.91	22.18	25.51
2022-12-31	71,150,270,270.27	14,419,459,459.46	13,428,108,108.11	72.74	26.55	18.87	20.27
2023-12-31	71,782,660,332.54	13,593,824,228.03	13,655,581,947.74	72.94	25.47	19.02	18.94
2024-12-31	68,792,723,263.51	16,631,753,031.97	9,125,689,084.9	73.9	21.5	13.27	24.18
2025-12-31	77,573,770,491.8	17,757,881,462.8	16,242,118,537.2	73.53	31.32	20.94	22.89

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	12.46	Trailing four quarters
2024-12-31	10.36	Trailing four quarters
2023-12-31	8.22	Trailing four quarters
2022-12-31	18.69	Annual net income
2021-12-31	23.34	Annual net income

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	860,000,000
2018-01-01	861,000,000
2019-01-01	865,772,700
2020-01-01	863,703,900
2021-01-01	857,465,900
2022-01-01	799,180,700
2023-01-01	804,000,000
2024-01-01	802,000,000
2025-01-01	803,000,000
2026-01-01	809,257,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.